You are here

Article Text

Article menu
Download PDFPDF
ePoster
EP773 Splenectomy as primary cytoreductive surgery in advanced stage epithelial ovarian cancer
  1. H Akilli1,
  2. L Aksoy Karakaş1,
  3. H Nihan2 and
  4. A Ayhan3
  1. 1Gynecology and Obstetrics
  2. 2Pathology
  3. 3Gynecology and Obstetrics, Division of Gynecologic Oncology, Baskent University Faculty of Medicine, Ankara, Turkey

Abstract

Introduction/Background The aim of the study was to evaluate site of splenic metastases and ıts affect on survival in advanced stage epithelial ovarian cancer.

Methodology This retrospective study was done in Baskent University School of Medicine, Ankara, Turkey. We evaluated 182 patients who underwent splenectomy as a part of primary cytoreductive surgery between 2008–2018 Besides we invastegated 2,3 and 5 year overall survival rates.

Results Median age was 61 years (27–81),Median lenght of stay was 13 days (4–87 days). 40 (21,7%) patients had paranchimal and 144 (78,3%) had non paranchimal (Hilar or capsular) metastases,Median overal survival was 27 months and 31 months respectively(p=0,6).

Conclusion Splenectomy in primary cytoreductive surgery is an effective intervention to achive R0 resection in advanced stage EOC However site of splenic metastases has no impact on short term and long term overall survival.

Disclosure Nothing to disclose.

View this table:
Abstract EP773 Table 1

Median Overall Survival rates According to site of Splenic Metastases

https://doi.org/10.1136/ijgc-2019-ESGO.824

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.